Muromonab-CD3

Patients with pre-existing fever or uncontrolled hypertension. Hypersensitivity to products of murine origin. Avoid in patients with a history of seizures. Patients with uncompensated heart failure or who have undergone a more than 3% weight gain in the wk preceding therapy or who have radiographic evidence of fluid overloading. Pregnancy and lactation.

Increases the risk of infections and certain malignancies. Caution when using IUDs due to an increased risk of infection. Avoid use of live vaccines. Repeated courses may be less effective due to formation of antibodies to the drug. Unstable angina, recent MI, ischaemic heart disease, heart failure, pulmonary oedema, COPD, vascular overload or depletion, septic shock, cerebrovascular disease, advanced symptomatic vascular disease or neuropathy, history of thrombotic events or underlying vascular disease. Children with primary Epstein-Barr viral infection. Assess volume status prior to therapy. Perform baseline and periodic renal, hepatic and haematopoietic tests. Monitor closely over 24 hr following each of the 1st few doses. Child ≤16 yr. If hypersensitivity is suspected, discontinue immediately and do not re-challenge.

Diaphoresis, vasodilation, anorexia, asthenia, chills, fatigue, lethargy, malaise, fever, arrhythmia, bradycardia, hypertension, hypotension, chest pain, tachycardia, vascular occlusion, convulsions, dizziness, headache, meningitis, tremor, diarrhoea, nausea, abdominal pain, vomiting, anaemia, leukocytosis, thrombocytopenia, oedema, arthralgia, myalgia, confusion, depression, nervousness, somnolence, renal dysfunction, abnormal chest sound, dyspnoea, hyperventilation, hypoxia, pneumonia, pulmonary oedema, respiratory congestion, wheezing, pruritus, rash, photophobia, tinnitus, leucopenia.

IV/Parenteral: C

Symptoms include hyperthermia, severe chills, myalgia, vomiting, diarrhoea, oedema, oliguria, pulmonary oedema, acute renal failure and microangiopathic haemolytic anaemia. Patients should be observed closely and supportive treatment given if necessary.

Increased toxicity with immunosuppressants (e.g. azathioprine, corticosteroids, ciclosporin). Increased risk of encephalopathy and CNS effects with indometacin.

Description:
Mechanism of Action: Muromonab-CD3 is a mouse monoclonal antibody against CD3 (T3). It binds to T-cell receptor-associated CD3 complex and depletes and alters T-cells. Thus, it exerts an immunosuppressant effect without affecting the bone marrow.

Store at 2-8°C. Do not freeze or shake.

Thuốc ức chế miễn dịch